28.02
前日終値:
$29.09
開ける:
$28.1
24時間の取引高:
690.23K
Relative Volume:
1.00
時価総額:
$3.13B
収益:
$418.33M
当期純損益:
$-252.07M
株価収益率:
-11.68
EPS:
-2.4
ネットキャッシュフロー:
$-238.84M
1週間 パフォーマンス:
-2.84%
1か月 パフォーマンス:
-12.63%
6か月 パフォーマンス:
-16.66%
1年 パフォーマンス:
-3.18%
Zai Lab Limited Adr Stock (ZLAB) Company Profile
ZLAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ZLAB
Zai Lab Limited Adr
|
28.02 | 3.24B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-14 | 開始されました | Morgan Stanley | Overweight |
| 2023-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 開始されました | Macquarie | Outperform |
| 2021-10-12 | 開始されました | Bernstein | Mkt Perform |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-04-15 | 開始されました | Guggenheim | Buy |
| 2019-07-12 | 開始されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
| 2019-01-29 | 開始されました | Credit Suisse | Outperform |
| 2018-11-21 | 開始されました | Jefferies | Buy |
| 2018-06-21 | 再開されました | Leerink Partners | Outperform |
| 2018-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 開始されました | JP Morgan | Neutral |
| 2017-10-16 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Zai Lab Limited Adr (ZLAB) 最新ニュース
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
Zai Lab Secures RMB300 Million Debt Facility - The Globe and Mail
[8-K] Zai Lab Ltd Reports Material Event | ZLAB SEC FilingForm 8-K - Stock Titan
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - The Globe and Mail
Operating cash flow per share of Zai Lab Ltd. Sponsored ADR – BER:1ZL - TradingView
Trip.com Group LimitedAmerican Depositary Shares (NQ: - FinancialContent
Is Zai Lab's Valuation Justified as Revenue Growth Lags the Biotech Industry (ZLAB)? - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
Zai Lab Limited Announces Equity Incentive Grants to Employees - MSN
Zai Lab (NASDAQ:ZLAB) Shares Gap UpStill a Buy? - MarketBeat
Zai Lab Limited Depositary Receipt Stock Analysis and ForecastStochastic Oscillator Alerts & High Profit Trading Signals - Early Times
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
How robust is Anheuser Busch Inbev SA Sponsored ADR stock financial position2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Zai Lab Limited Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsZLAB - ACCESS Newswire
Acadian Asset Management LLC Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into Zai Lab Limited (ZLAB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Lost Money on Zai Lab Limited (ZLAB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zai Lab Limited (ZLAB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Insider Buying: Zai Lab (NASDAQ:ZLAB) Insider Purchases 10,000 Shares of Stock - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages - Defense World
Woodline Partners LP Sells 558,781 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownTime to Sell? - MarketBeat
Zai Lab Limited ADR (NASDAQ: ZLAB) Is Up 14.37% – Is It Capable Of A Rally? - stocksregister.com
FY2026 EPS Estimates for Zai Lab Reduced by Leerink Partnrs - MarketBeat
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB) - 富途牛牛
Raymond James Financial Inc. Boosts Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Cubist Systematic Strategies LLC Increases Stake in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
Zai Lab under pressure over clinical results and rival drugs - thebambooworks.com
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs - Defense World
Canada Pension Plan Investment Board Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
MPM Bioimpact LLC Acquires 33,659 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab LimitedZLAB - FinancialContent
Raymond James Financial Inc. Has $4.55 Million Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - Defense World
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce… - inkl
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAcadian Asset Management (NYSE:AAMI), C3.ai (NYSE:AI) - Benzinga
Zai Lab: to await results of Fortitude-102 prior to reg. filing - AInvest
ZAI LAB Plunges ~13% on Heavy Trading as Amgen's Bemarituzumab Final Analysis Shows Weaker Survival Benefit - AASTOCKS.com
Stocks Showing Rising Market Leadership: Zai Lab ADR Earns 82 RS Rating - Investor's Business Daily
First ADC Therapy for Cervical Cancer: Zai Lab's TIVDAK Gets Hong Kong Regulatory Green Light - Stock Titan
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Business Wire
Zai Lab Limited Unsponsored ADR $ZLAB Shares Purchased by Invesco Ltd. - Defense World
How high can Zai Lab Limited Depositary Receipt stock goTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - Newser
Zai Lab Announces Participation in Investor Conferences in June 2025 - FinancialContent
Zai Lab Limited Depositary Receipt stock chart pattern explained2025 Geopolitical Influence & Weekly Breakout Watchlists - Newser
Can trapped investors hope for a rebound in Zai Lab Limited Depositary Receipt2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Zai Lab Limited Adr (ZLAB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):